INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $441,884 | +38.0% | 23,834 | 0.0% | 0.00% | – |
| Q2 2023 | $320,090 | 0.0% | 23,834 | 0.0% | 0.00% | – |
| Q1 2023 | $320,090 | -6.2% | 23,834 | -13.6% | 0.00% | – |
| Q4 2022 | $341,154 | -99.8% | 27,579 | +118.3% | 0.00% | – |
| Q3 2022 | $176,202,000 | -45.5% | 12,631 | -46.1% | 0.00% | – |
| Q2 2022 | $323,471,000 | -20.8% | 23,423 | -6.7% | 0.00% | – |
| Q1 2022 | $408,522,000 | -0.1% | 25,109 | 0.0% | 0.00% | – |
| Q4 2021 | $409,026,000 | +9.7% | 25,109 | 0.0% | 0.00% | – |
| Q3 2021 | $372,869,000 | -25.6% | 25,109 | 0.0% | 0.00% | – |
| Q2 2021 | $501,428,000 | +72.0% | 25,109 | +98.8% | 0.00% | – |
| Q1 2021 | $291,523,000 | -6.6% | 12,631 | 0.0% | 0.00% | – |
| Q4 2020 | $311,985,000 | -95.3% | 12,631 | -92.1% | 0.00% | -100.0% |
| Q3 2020 | $6,654,993,000 | -16.5% | 160,516 | -3.5% | 0.00% | -20.0% |
| Q2 2020 | $7,965,805,000 | -24.9% | 166,266 | -1.3% | 0.01% | -37.5% |
| Q1 2020 | $10,609,326,000 | -53.3% | 168,509 | -8.0% | 0.01% | -42.9% |
| Q4 2019 | $22,702,763,000 | +115.0% | 183,205 | +15.1% | 0.01% | +100.0% |
| Q3 2019 | $10,560,465,000 | -15.5% | 159,139 | +1.3% | 0.01% | -22.2% |
| Q2 2019 | $12,495,752,000 | +16.3% | 157,041 | +63.5% | 0.01% | +12.5% |
| Q1 2019 | $10,741,244,000 | +14.5% | 96,024 | +3.2% | 0.01% | 0.0% |
| Q4 2018 | $9,381,332,000 | -36.1% | 93,078 | -19.8% | 0.01% | -27.3% |
| Q3 2018 | $14,672,293,000 | +1582.0% | 116,115 | +1016.9% | 0.01% | +1000.0% |
| Q2 2018 | $872,329,000 | +46.5% | 10,396 | +7.4% | 0.00% | – |
| Q1 2018 | $595,514,000 | +5.3% | 9,680 | 0.0% | 0.00% | – |
| Q4 2017 | $565,505,000 | +5.6% | 9,680 | +4.9% | 0.00% | – |
| Q3 2017 | $535,419,000 | -97.1% | 9,225 | -93.9% | 0.00% | -100.0% |
| Q2 2017 | $18,325,519,000 | +3.1% | 151,363 | -3.7% | 0.02% | 0.0% |
| Q1 2017 | $17,780,112,000 | +124253.8% | 157,207 | +19.5% | 0.02% | +12.5% |
| Q4 2016 | $14,298,000 | -35.9% | 131,600 | -3.0% | 0.02% | -33.3% |
| Q3 2016 | $22,321,000 | +13.3% | 135,620 | -1.8% | 0.02% | +9.1% |
| Q2 2016 | $19,706,000 | +7.6% | 138,117 | -3.1% | 0.02% | +4.8% |
| Q1 2016 | $18,318,000 | -10.3% | 142,585 | +4.3% | 0.02% | -8.7% |
| Q4 2015 | $20,423,000 | -9.9% | 136,742 | +0.1% | 0.02% | -8.0% |
| Q3 2015 | $22,661,000 | -36.6% | 136,626 | -7.7% | 0.02% | -26.5% |
| Q2 2015 | $35,721,000 | -1.5% | 147,988 | +15.1% | 0.03% | -2.9% |
| Q1 2015 | $36,247,000 | +89.8% | 128,525 | +5.0% | 0.04% | +94.4% |
| Q4 2014 | $19,099,000 | -13.3% | 122,425 | +31.5% | 0.02% | -18.2% |
| Q3 2014 | $22,041,000 | +4.4% | 93,125 | +4.4% | 0.02% | +4.8% |
| Q2 2014 | $21,107,000 | -22.1% | 89,200 | +8.5% | 0.02% | -27.6% |
| Q1 2014 | $27,109,000 | +265.9% | 82,200 | -24.2% | 0.03% | +262.5% |
| Q4 2013 | $7,408,000 | – | 108,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |